ArticleCytotechnology2025
Guizhi fuling decoction inhibits pyroptosis to improve high-fat diet-induced obesity by up-regulating ACE2.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity has become a global public problem. Guizhi Fuling Decoction (GZFLD) is a traditional Chinese medicine decoction. This study aims to investigate the therapeutic effects of GZFLD on high-fat diet (HFD)-induced obesity in mice. The obese mouse model was induced by HFD. The effects of GZFLD on obesity were assessed by recording body weight (BW) and inguinal white adipose tissue (Ing-WAT) weight of mice. Histological changes in adipose and liver tissues were evaluated by hematoxylin-eosin staining. Enzyme-linked immunosorbent assay was exploited to detect the expression of blood lipid indexes and inflammatory factors. The expression of pyroptosis-related proteins was detected by western blot and immunohistochemistry. Transcriptome sequencing was executed to explore the mechanism of GZFLD on obese mice and screen the pyroptosis-related genes. Furthermore, the effect of Angiotensin-converting enzyme 2 (ACE2) on obese mice was verified by ACE2 inhibitor-DX600. In HFD-induced mice, with the increased dose of GZFLD, GZFLD significantly improved obesity, hepatic steatosis and dyslipidemia, with decreased BW, Ing-WAT weight, Ing-WAT/BW ratio, levels of triglycerides, cholesterol low-density lipoprotein, and increased high-density lipoprotein levels. Hematoxylin-eosin staining exhibited that GZFLD improved steatosis and adipocyte enlargement induced by HFD. Additionally, GZFLD suppressed the levels of lactate dehydrogenase, inflammation factors, and pyroptosis-related proteins. RNA-sequencing identified ACE2 as a key gene target. The ACE2 inhibitor DX600 attenuated the inhibitory effects of GZFLD on hepatic steatosis, dyslipidemia, inflammation, and pyroptosis in HFD-induced obese mice. Collectively, GZFLD had a protective effect on HFD-induced obesity by alleviating dyslipidemia, and inhibiting inflammation and pyroptosis, which was achieved by up-regulating ACE2. Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-025-00848-x.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.